Outlook Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.32 Insider Own0.70% Shs Outstand219.07M Perf Week-6.42%
Market Cap230.50M Forward P/E- EPS next Y-0.16 Insider Trans21.50% Shs Float132.51M Perf Month-4.67%
Income-59.80M PEG- EPS next Q-0.07 Inst Own12.00% Short Float8.05% Perf Quarter-42.70%
Sales- P/S- EPS this Y48.30% Inst Trans4.73% Short Ratio9.77 Perf Half Y-26.62%
Book/sh0.16 P/B6.37 EPS next Y48.10% ROA-118.30% Target Price6.92 Perf Year-59.20%
Cash/sh0.26 P/C3.95 EPS next 5Y- ROE-234.10% 52W Range0.68 - 3.27 Perf YTD-25.00%
Dividend- P/FCF- EPS past 5Y58.80% ROI- 52W High-65.75% Beta0.87
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin- 52W Low63.77% ATR0.11
Employees9 Current Ratio2.10 Sales Q/Q- Oper. Margin- RSI (14)49.66 Volatility6.15% 9.02%
OptionableNo Debt/Eq0.63 EPS Q/Q-3.50% Profit Margin- Rel Volume0.70 Prev Close1.02
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.09M Price1.12
Recom2.00 SMA2011.20% SMA50-15.48% SMA200-31.34% Volume669,485 Change9.80%
Sep-11-19Initiated Ladenburg Thalmann Buy $9
May-16-19Initiated Oppenheimer Outperform $12
Apr-22-19Initiated Ascendiant Capital Markets Buy
Jul-05-22 08:05AM  
Jun-14-22 08:05AM  
May-31-22 08:05AM  
May-27-22 07:25AM  
May-18-22 08:05AM  
May-13-22 08:05AM  
May-10-22 08:35AM  
May-09-22 08:35AM  
May-04-22 12:02PM  
Apr-22-22 08:05AM  
Apr-05-22 08:05AM  
Apr-04-22 07:45PM  
Mar-31-22 08:05AM  
Mar-03-22 08:05AM  
Feb-24-22 08:05AM  
Feb-16-22 10:59AM  
Feb-14-22 08:05AM  
Feb-10-22 08:05AM  
Feb-08-22 08:05AM  
Feb-02-22 05:38PM  
Jan-25-22 08:05AM  
Jan-19-22 08:05AM  
Jan-12-22 10:35AM  
Jan-04-22 08:35AM  
Dec-22-21 08:05AM  
Dec-15-21 08:05AM  
Dec-09-21 08:05AM  
Nov-29-21 04:15PM  
Nov-24-21 06:49AM  
Nov-23-21 10:30PM  
Nov-13-21 11:00AM  
Nov-10-21 08:05AM  
Nov-04-21 02:30PM  
Nov-03-21 08:05AM  
Oct-15-21 08:41AM  
Oct-12-21 12:00PM  
Oct-07-21 08:05AM  
Oct-05-21 08:05AM  
Sep-28-21 08:05AM  
Sep-21-21 08:05AM  
Sep-13-21 08:05AM  
Sep-08-21 08:05AM  
Aug-26-21 09:57AM  
Aug-13-21 08:05AM  
Aug-11-21 08:05AM  
Aug-03-21 05:34PM  
Jul-07-21 08:05AM  
Jul-02-21 05:04AM  
Jun-14-21 08:05AM  
Jun-08-21 08:05AM  
May-27-21 08:05AM  
May-18-21 06:15AM  
May-14-21 08:05AM  
May-12-21 08:05AM  
Mar-31-21 09:23AM  
Mar-23-21 04:49AM  
Mar-04-21 09:00AM  
Feb-17-21 08:05AM  
Feb-16-21 08:05AM  
Feb-11-21 08:05AM  
Feb-04-21 11:18AM  
Feb-02-21 04:05PM  
Jan-28-21 11:59PM  
Jan-12-21 08:05AM  
Jan-05-21 08:00AM  
Dec-23-20 09:05AM  
Dec-07-20 08:04PM  
Dec-01-20 08:05AM  
Nov-19-20 08:05AM  
Nov-11-20 09:05AM  
Nov-05-20 08:05AM  
Nov-03-20 08:35AM  
Oct-22-20 08:00AM  
Oct-13-20 08:05AM  
Oct-12-20 03:30PM  
Oct-07-20 08:05AM  
Sep-30-20 08:05AM  
Sep-08-20 08:05AM  
Aug-26-20 02:52PM  
Aug-14-20 08:05AM  
Jul-17-20 08:05AM  
Jul-07-20 08:05AM  
Jun-25-20 09:43AM  
Jun-23-20 08:00AM  
Jun-17-20 08:05AM  
Jun-11-20 08:05AM  
Jun-10-20 08:12PM  
Jun-09-20 08:05AM  
Jun-03-20 08:05AM  
May-26-20 08:05AM  
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TRENARY C RUSSELL IIICEO and PresidentJun 21Buy1.0619,92521,12054,925Jun 23 05:07 PM
Dagnon TerryChief Operating OfficerJun 21Buy1.0510,00010,5001,173,058Jun 23 05:08 PM
HILZINGER KURT JDirectorMar 01Buy1.6927,70846,827273,117Mar 03 05:30 PM
HILZINGER KURT JDirectorFeb 28Buy1.606,0009,600245,409Feb 28 05:57 PM
HILZINGER KURT JDirectorFeb 24Buy1.4641,16060,094239,409Feb 28 05:57 PM
HILZINGER KURT JDirectorFeb 23Buy1.4479,535114,530198,249Feb 23 05:42 PM
HILZINGER KURT JDirectorFeb 22Buy1.4995,597142,440118,714Feb 23 05:42 PM
TRENARY C RUSSELL IIICEO and PresidentDec 06Buy1.3925,00034,75035,000Dec 06 05:27 PM
Dagnon TerryChief Operating OfficerDec 06Buy1.3825,20134,7771,163,058Dec 06 05:26 PM
Dagnon TerryChief Operating OfficerDec 03Buy1.4210,00014,2001,137,857Dec 03 04:32 PM
Evanson JeffChief Commercial OfficerDec 03Buy1.3435,20047,1681,177,130Dec 06 05:25 PM
Sukhtian Faisal GhiathDirectorDec 02Buy1.4018,00025,20038,000Dec 02 05:08 PM
Haddadin Yezan MuntherDirectorDec 02Buy1.3910,00013,90030,000Dec 02 05:09 PM
TRENARY C RUSSELL IIICEO and PresidentDec 02Buy1.4010,00014,00010,000Dec 02 05:07 PM
Sukhtian Ghiath M.DirectorNov 29Buy1.2516,000,00020,000,00027,834,257Dec 01 07:32 PM